Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendrikx JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S.

Clin Cancer Res. 2019 Sep 15;25(18):5466-5474. doi: 10.1158/1078-0432.CCR-17-2299. Epub 2019 Jun 19.

PMID:
31217201
2.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

de Weger VA, Stuurman FE, Hendrikx JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S.

Eur J Cancer. 2017 Nov;86:217-225. doi: 10.1016/j.ejca.2017.09.010. Epub 2017 Oct 12.

PMID:
29031170
3.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B.

Drug Deliv Transl Res. 2013 Jun;3(3):243-51. doi: 10.1007/s13346-012-0127-6.

PMID:
25788133
4.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Moes JJ, Koolen SL, Huitema AD, Schellens JH, Beijnen JH, Nuijen B.

Int J Pharm. 2011 Nov 28;420(2):244-50. doi: 10.1016/j.ijpharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21907780
5.

Application of process analytical technology in tablet process development using NIR spectroscopy: blend uniformity, content uniformity and coating thickness measurements.

Moes JJ, Ruijken MM, Gout E, Frijlink HW, Ugwoke MI.

Int J Pharm. 2008 Jun 5;357(1-2):108-18. doi: 10.1016/j.ijpharm.2008.01.062. Epub 2008 Mar 10.

PMID:
18394831

Supplemental Content

Support Center